바이오앤테크 (BNTX)

Shares of BioNTech Se (BNTX) dropped by 6.38% from $103.58 to $96.97 in the trading on Monday, October 16, 2023. The reasons why BNTX stock down include:

• Pfizer's sales outlook cut: BioNTech's partner, Pfizer, decided to slash its full-year sales expectations by $9 billion, citing a shift towards the commercial approval of its Paxlovid COVID treatment and other factors. The impact of Pfizer's news rippled through the pharmaceutical sector, causing declines in the shares of BioNTech.
• Downgrade rating: BioNTech received a downgrade from HSBC research analysts on Monday. They changed their rating from Buy to hold in a research report distributed to clients and investors, as reported by Marketbeat.com. Additionally, they revised their price target for the stock from $124.00 to $111.00. This indicates a more neutral stance on BioNTech's prospects, reflecting a potential shift in market sentiment or the analysts' assessment of the company's current position.